Fig. 2.
Non-ocular treatment-emergent adverse events reported in ≥ 5% of patients treated with varenicline solution 0.03 mg or vehicle in each nostril twice daily in the ONSET-2 trial [26]. VAR varenicline solution, VEH vehicle
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.